Barry M - Search Results

1

The Utility of a Rapid Review Evaluation Process to a National HTA Agency.

Varley Á, Tilson L, Fogarty E, McCullagh L, Barry M. Varley Á, et al. Among authors: barry m. Pharmacoeconomics. 2022 Feb;40(2):203-214. doi: 10.1007/s40273-021-01093-8. Epub 2021 Oct 12. Pharmacoeconomics. 2022. PMID: 34635994 Free PMC article. Review.

2

The high cost of medicines in Ireland. Is it time to change the pricing mechanism?

Tilson L, McGowan B, Bennett K, Barry M. Tilson L, et al. Among authors: barry m. Eur J Health Econ. 2004 Dec;5(4):341-4. doi: 10.1007/s10198-004-0245-2. Eur J Health Econ. 2004. PMID: 15452737

3

Pricing and reimbursement of drugs in Ireland.

Barry M, Tilson L, Ryan M. Barry M, et al. Eur J Health Econ. 2004 Jun;5(2):190-4. doi: 10.1007/s10198-004-0225-6. Eur J Health Econ. 2004. PMID: 15452757

4

The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland.

Tilson L, Bennett K, Barry M. Tilson L, et al. Among authors: barry m. Eur J Health Econ. 2005 Sep;6(3):267-73. doi: 10.1007/s10198-005-0302-5. Eur J Health Econ. 2005. PMID: 15977036

5

Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.

Tilson L, Thornton L, O'Flanagan D, Johnson H, Barry M. Tilson L, et al. Among authors: barry m. Eur J Public Health. 2008 Jun;18(3):275-82. doi: 10.1093/eurpub/ckm123. Epub 2007 Dec 26. Eur J Public Health. 2008. PMID: 18160389

6

Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland.

Tilson L, Usher C, Butler K, Fitzsimons J, O'Hare F, Cotter S, O'Flanagan D, Johnson H, Barry M. Tilson L, et al. Among authors: barry m. Value Health. 2008 Sep-Oct;11(5):898-903. doi: 10.1111/j.1524-4733.2008.00341.x. Epub 2008 May 16. Value Health. 2008. PMID: 18489504 Free article.

7

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.

Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M. Usher C, et al. Among authors: barry m. Vaccine. 2008 Oct 16;26(44):5654-61. doi: 10.1016/j.vaccine.2008.07.098. Epub 2008 Aug 22. Vaccine. 2008. PMID: 18723068

8

Cost-effectiveness of treatments reducing coronary heart disease mortality in Ireland, 2000 to 2010.

Bennett K, Kabir Z, Barry M, Tilson L, Fidan D, Shelley E, Capewell S. Bennett K, et al. Among authors: barry m. Value Health. 2009 Jan-Feb;12(1):10-5. doi: 10.1111/j.1524-4733.2008.00398.x. Epub 2008 Jul 15. Value Health. 2009. PMID: 19040564 Free article.

9

A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.

McCullagh L, Tilson L, Walsh C, Barry M. McCullagh L, et al. Among authors: barry m. Pharmacoeconomics. 2009;27(10):829-46. doi: 10.2165/11313800-000000000-00000. Pharmacoeconomics. 2009. PMID: 19803538

10

Pharmacoeconomic evaluation in Ireland: a review of the process.

Tilson L, O'Leary A, Usher C, Barry M. Tilson L, et al. Among authors: barry m. Pharmacoeconomics. 2010;28(4):307-22. doi: 10.2165/11318790-000000000-00000. Pharmacoeconomics. 2010. PMID: 20222754

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,323 results

Search Page

Filters